Trial Profile
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Infants
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs GSK 3389245A (Primary) ; Meningococcal vaccine group B OMV Novartis; Meningococcal vaccine groups A C Y W-135 conjugate; Pneumococcal 10-valent vaccine conjugate
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Acronyms RSV PED-011
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
- 12 Jul 2023 Results published in the Journal of Infectious Diseases
- 10 Sep 2021 Status changed from active, no longer recruiting to completed.
- 29 Aug 2021 This trial has been completed in Finland.